Atara Biotherapeutics, Inc. (ATRA) 株式分析

企業概要

Atara Biotherapeutics, Inc. is an entity engaged in the development and commercialization of transformative therapies designed to address cancer and autoimmune diseases for patients in both the United States and international markets. The company operates within the Healthcare sector, specifically the Biotechnology industry, a domain characterized by high capital requirements for research and development and significant regulatory hurdles for product approval. At the time of analysis, the company's market capitalization stands at $39.50M, while its trailing twelve-month revenue amounts to $120.77M with a workforce of 14 employees. These valuation and revenue figures indicate that the company maintains a relatively small market presence compared to established pharmaceutical giants, reflecting a typical profile for a clinical-stage biotechnology firm where significant value is derived from future potential rather than current scale. The disparity between the substantial revenue figure and the modest market cap suggests a specific market dynamic where the stock price may not fully reflect the reported top-line performance, a phenomenon often seen in biotech assets with unique revenue recognition models or pending clinical outcomes.

財務健全性

The financial statements reveal a trailing twelve-month revenue of $120.77M and a net income of $32.69M, resulting in an EBITDA of $51.59M. The gap between the reported net income and revenue, combined with the EBITDA figure, reveals a complex cost structure where non-cash expenses or specific accounting treatments significantly impact the bottom line relative to operating earnings. Despite the positive net income, the free cash flow is reported at $-47,677,624, which indicates that the company is consuming cash to fund its operations and development activities, thereby limiting its current financial flexibility and reliance on external capital sources. The margin analysis shows a gross margin of 61.8%, which is healthy for a biotechnology company, but an operating margin of -339.6% and a profit margin of 27.1% that presents an anomalous relationship, suggesting that while the core product sales are profitable, operating expenses are being calculated or presented in a manner that results in a negative operating figure. On the balance sheet, the company holds $8.48M in cash against $10.38M in debt, and the debt-to-equity ratio is listed as N/A, indicating a capital structure that is highly leveraged relative to its equity base or where equity is negligible. The current ratio stands at 0.82, which indicates that the company's current liabilities exceed its current assets, signaling potential short-term liquidity challenges that require careful management. Return on Equity is N/A due to the lack of positive equity, while the return on assets is 47.8%, which suggests that the company is generating significant earnings relative to its total asset base, highlighting an efficient use of assets despite the liquidity constraints.

バリュエーション評価

The valuation metrics present a trailing P/E ratio of 1.88 and a forward P/E of 5.96. The significant difference between these two ratios implies that the market expects earnings to expand rapidly in the future, as the forward multiple is more than three times the trailing multiple, although the underlying drivers for this expansion must be scrutinized given the current financial context. The price-to-book ratio is -0.92, which indicates that the market values the company at a negative premium relative to its book value, a metric that often reflects intangible assets or specific accounting structures in biotechnology rather than traditional manufacturing assets. Alternative valuation measures such as the price-to-sales ratio of 0.33 and the EV/EBITDA of 0.80 suggest that the company is priced very cheaply relative to its revenue and earnings power, potentially indicating a deep value opportunity or significant market skepticism regarding future execution. The stock has traded between a 52-week high of $19.14 and a 52-week low of $3.92, and without the specific current price to calculate the exact percentage, the wide range demonstrates substantial volatility typical of small-cap biotechnology stocks. The beta value of -0.33 is highly unusual for an equity security, suggesting an inverse correlation to the broader market or data irregularity, which implies that the stock's price movements do not follow the standard risk profile of the overall market.

Growth & Income

The company reports a revenue growth rate of -95.1% year-over-year, while earnings growth is N/A. The negative revenue growth indicates a sharp contraction in sales, which is inconsistent with the positive net income reported, suggesting that the revenue figure used for growth calculation may differ from the TTM revenue or involves specific adjustments not detailed in the summary. Since the earnings growth is N/A, a direct comparison of earnings versus revenue growth rates cannot be made, but the negative revenue trajectory implies a challenging environment for the company's commercialization efforts. The company does not pay a dividend, evidenced by a dividend yield of N/A and a payout ratio of 0.0%, which means all available earnings are retained within the company rather than distributed to shareholders. Consequently, the company reinvests its earnings back into research, development, and operational needs to attempt to reverse the negative revenue trend and advance its lead product programs. The overall growth and income profile is characterized by negative revenue momentum, zero dividend income, and a reliance on internal retention of profits to sustain operations amidst significant cash burn and liquidity pressures.